project bioshield act act passed united states congress calling billion purchasing vaccines would used event bioterrorist tenyear program acquire medical countermeasures biological chemical radiological nuclear agents civilian use key element act allow stockpiling distribution vaccines tested safety efficacy humans due ethical concerns efficacy agents directly tested humans without also exposing humans chemical biological radioactive threat treated testing follows fda animal rule pivotal animal since terrorist attacks united states government allocated nearly billion address threat biological weapons us funding bioweaponsrelated activities focuses primarily research acquisition medicines defense funding also goes toward stockpiling protective equipment increased surveillance detection biological agents improving state hospital preparedness increase type funding mainly project bioshield significant funding also goes biomedical advanced research development authority barda part hhs funding activities aimed prevention doubled distributed federal efforts toward cooperative international action part project progress made establishment national requirements acquisition strategies well procurement pre postexposure countermeasures meet threat anthrax botulinum toxins smallpox radiological nuclear threats united states department health human services hhs taken number additional steps accomplish goal effectively efficiently implementing project bioshield act hhs reorganized assistant secretary preparedness response aspr formerly office public health emergency preparedness established dedicated strategic planning function efficiently integrates biodefense requirements streamlines interagency governance process reorganized structure behalf secretary hhs aspr leads federal public health medical response acts terrorism nature public health medical emergencies hhs announced federal register notice july establishment public health emergency medical countermeasures enterprise september bioprepwatch reported barda annual report shows number supplies countermeasures combating terrorist attacks according report barda section pandemic allhazards preparedness reauthorization act hr congress reauthorized bioshield specifically reauthorizes project bioshield special reserve fund srf originally established june eight medical countermeasures mcm anthrax smallpox botulinum toxin radiological threats procured eighty candidate mcms undergoing advanced development authorities funds contained project bioshield act slated expire end year legislative experiment bioshield subject evaluation reconsideration house senate passed versions reauthorization march funding extended via pandemic actpandemic allhazards preparedness reauthorization act us department health human services march retrieved feb february bipartisan policy center released report called budgeting medical countermeasures ongoing need preparedness based report former us senator tom daschle dsd said change way project bioshield act funded changed tenyear appropriations cycle yearbyyear funding creates climate uncertainty private firms looking invest medical countermeasures mcm chemical biological radiological nuclear cbrn agents commercial market exists mcms firms research develop mcms depend reliable stream government money according homeland preparedness news daschle former us sen judd gregg offered budgeting strategies believe could lend stability mcm arena would call changes statutory processes congressional procedures implemented since project bioshield acts review reported project advanced appropriation vaccines biodosimetry biological weapons provisions made well ensure safer effective vaccinations threats smallpox another issue lies within us food drug administration fda fda requires clinical studies human safety efficacy journal american osteopathic association notes kind testing biological weapons ethically unacceptable conduct humans need expedited development critical countermeasures must balanced need ensure essential interventions safe well review stated project needed market government high risk failure low expectation profit discourages manufacturers investing research development funds bioterrorism products sold expected profits justify opportunity costs pharmaceutical vaccine manufacturers perceive federal government uncertain lowprofit market project developed attempt provide financial incentive manufacturers develop products needed defense cbrn perspective piece published new england journal medicine noted fda issued emergency use authorization eua use unapproved drug case emergency also noted could issued secretary health human services declared public health emergency case influenza pandemic declaration made april eua medical product term one year renewed depending circumstances emergency important product development continue focus goal approval ongoing clinical trials evaluating efficacy intravenous peramivir treating influenza eua temporary means making product available book published stated project allows secretary health human services purchase unapproved unlicensed vaccinations hhs determine sufficient satisfactory clinical experience research datasupports reasonable conclusion product qualify approval licensingwithin eight hhs write contracts unapproved products help lowering purchasing cost drugs provisions project bioshield controversial critics suggest biotechnology pharmaceutical companies require even incentives contained proposals government projects funding would subject annual review appropriations process furthermore law would require hhs secretary prepare annual reports detailing actions taken act including identification person entity received considered rejected grants cooperative agreements contracts act approval licensing processes designed preclude marketing ineffective dangerous treatments drugs begin approval process actually become approved treatments possible predict outcome approval process critics provision suggest government end purchasing countermeasures eventually fail obstacles pharmaceutical vaccine development include inadequate funding research insufficient protections corporate liability constraints related safety considerations typically drugdevelopment process united states largely initiated national institutes health supports basic research funding scientists although development new medication usually takes several years time research begins time medication marketed developing medical interventions potential biological weapons especially intense terms time labor also guarantee drug companies purchase vaccinations chief medical officer biomedical preparedness pharmaceutical research manufacturers america washington dc voiced additional financial concerns pharmaceutical industry michael friedman md explains manufacturers biological defense products could still exposed devastating productliability suits adding decision divert resources research development medicines serious illnesses like heart disease financially risky especially countermeasure may never purchased used friedman argues needs sponsored research collaborative programs engage government academia industry well additional incentives private httpsenwikipediaorgwikiprojectbioshieldact